Chatterjee Neal A, Heist E Kevin
Cardiology Division and Cardiac Arrhythmia Service, Massachusetts General Hospital, Harvard Medical School, 55 Fruit Street, Boston, MA, 02114, USA.
Cardiology Division of the Department of Medicine, Massachusetts General Hospital, Harvard Medical School, Boston, MA, 02114, USA.
Curr Treat Options Cardiovasc Med. 2018 Mar 6;20(3):20. doi: 10.1007/s11936-018-0614-2.
Cardiac resynchronization therapy (CRT) is an important therapeutic tool in the management of patients with heart failure and electrical dyssynchrony. In appropriately selected patients, landmark randomized controlled trials have demonstrated morbidity and mortality benefit beyond standard goal-directed medical therapy. Current guidelines emphasize the greatest clinical efficacy of CRT in patients with symptomatic heart failure, left bundle branch block, and wide QRS duration (> 150 ms). Other relevant considerations include the presence of atrial fibrillation, the presence of AV block, the etiology of cardiomyopathy, the presence of masked left-sided conduction delay, and the impact of comorbidities that might predict poor clinical response. At the time of CRT implantation, key considerations include targeting of the left ventricular (LV) lead to sites of greatest electrical and/or mechanical delay, the use of quadripolar versus bipolar LV pacing leads, evaluation of multiple pacing vectors to maximize electrical resynchronization, and in select instances pre-procedure imaging of the coronary venous anatomy to help guide decision-making at the time implant. Post-implant care includes the selective use of atrio-ventricular and inter-ventricular optimization algorithms, mitigation of right ventricular pacing, recognition, and treatment of suboptimal biventricular pacing, as well as management by a multi-disciplinary team of cardiovascular specialists. Emerging therapeutic strategies for patients eligible for CRT include the use of endocardial LV pacing, novel LV pacing options including multi-point pacing, His bundle pacing, and the integration of remote monitoring platforms that may identify patients at risk for clinical worsening.
心脏再同步治疗(CRT)是治疗心力衰竭和电不同步患者的重要治疗手段。在适当选择的患者中,具有里程碑意义的随机对照试验表明,CRT较标准的目标导向药物治疗能降低发病率和死亡率。当前指南强调,CRT对有症状心力衰竭、左束支传导阻滞且QRS波时限较宽(>150毫秒)的患者临床疗效最佳。其他相关考虑因素包括是否存在心房颤动、房室传导阻滞、心肌病的病因、是否存在隐匿性左侧传导延迟以及可能预示临床反应不佳的合并症的影响。在植入CRT时,关键考虑因素包括将左心室(LV)导线放置在电和/或机械延迟最大的部位、使用四极与双极LV起搏导线、评估多个起搏向量以最大化电同步,以及在某些情况下对冠状静脉解剖结构进行术前成像以辅助植入时的决策制定。植入后护理包括选择性使用房室和心室间优化算法、减少右心室起搏、识别和治疗双心室起搏效果欠佳的情况,以及由心血管专科多学科团队进行管理。适用于CRT患者的新兴治疗策略包括使用心内膜LV起搏、新型LV起搏选项,如多点起搏、希氏束起搏,以及整合可识别临床病情恶化风险患者的远程监测平台。